title: Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy.
abstract: OBJECTIVE
  To investigate the effects of topical pranoprofen 0.1 % on acute central serous chorioretinopathy (CSC).
  
  
  METHODS
  The medical records of 52 cases (52 patients) of CSC were retrospectively reviewed. Twenty-six patients were treated with topical pranoprofen 0.1 % (treatment group) and 26 patients did not receive treatment (control group). Baseline and follow-up values for visual acuity, subfoveal choroidal thickness (SCT), subretinal fluid (SRF) maximum height, and central macular thickness (CMT) were examined and compared between groups.
  
  
  RESULTS
  In the treatment group, mean SCT decreased from 365.5 ± 52.9 μm at baseline to 288.9 ± 36.1 μm at 6 months after initiation of treatment (p = 0.005). Both SRF maximum height and CMT were also decreased from baseline at 1 month (SRF maximum height, baseline: 221.5 ± 108.4, 1 month: 97.7 ± 54.3 μm, p = 0.002; CMT, baseline: 403.9 ± 114.6, 1 month: 270.1 ± 37.9 μm, p = 0.003). In the control group, SCT decreased throughout the follow-up period, but the change was not significant. Subretinal fluid maximum height and CMT were significantly decreased after 3 months in the control group (SRF, baseline: 265.4 ± 112.4 μm, 6 months: 64.8 ± 116.9 μm, p = 0.005; CMT, baseline: 459.1 ± 104.9 μm, 6 months: 304.6 ± 92.8 μm, p < 0.001). Visual acuity was improved from baseline in both groups after 6 months, but the improvement was only significant in the treatment group (p = 0.002). The rate of disease recurrence was lower in the treatment group (23 %) than in the control group (38 %), but this difference between groups was not statistically significant (p = 0.229, chi-square test).
  
  
  CONCLUSIONS
  Topical pranoprofen 0.1 % was effective in treating acute CSC, as demonstrated by an increase in visual acuity and a decrease in SRF, SCT, and CMT after treatment. These results suggest that topical pranoprofen 0.1 % may be useful in treating patients with acute CSC.
authors.affiliation: Department of Ophthalmology, Dong-A University Hospital, 3-1. Dongdaeshin-Dong, Seo-gu, Busan, 602-715, Republic of Korea.
authors.forename: Seoung Hyun
authors.initials: SH
authors.lastname: An
authors.affiliation: Department of Ophthalmology, Dong-A University Hospital, 3-1. Dongdaeshin-Dong, Seo-gu, Busan, 602-715, Republic of Korea. yhkwon@dau.ac.kr.
authors.forename: Yoon Hyung
authors.initials: YH
authors.lastname: Kwon
mesh_terms: D000208:Acute Disease; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D001578:Benzopyrans / Q000008:administration & dosage*; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002829:Choroid / Q000000981:diagnostic imaging; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011422:Propionates / Q000008:administration & dosage*; D012160:Retina / Q000000981:diagnostic imaging; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001578:Benzopyrans; D009883:Ophthalmic Solutions; D011422:Propionates; C043940:pyranoprofen
keywords: Central serous chorioretinopathy; Choroidal thickness; Nonsteroidal anti-inflammatory drug; Pranoprofen; Topical